

# Temporal association between antibiotic use and resistance in Gram-negative bacteria

Wael Mansy<sup>1\*</sup>, Muzaheed<sup>2</sup>, Sanjay Rathod<sup>3</sup>

<sup>1</sup>Clinical Pharmacy Department, College of Pharmacy, King Saud University, KSA. <sup>2</sup>Assistant Professor, Department of Clinical Laboratory Science, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, KSA. <sup>3</sup>Lecturer, Department of Post Graduate Studies and Research in Microbiology, Gulbarga University, Gulbarga, India.

## Abstract

**Background:** The present investigation has attempted to enhance the understanding of the occurrence of interaction at a time between antibiotic usages with resistance ability of antimicrobial pathogens. **Methods and materials:** The collection of data on prescription and consumption of antibiotics and database on susceptibility covering isolation rate of resistance potential per quarter was collected. **Results:** The prescription rate of third-generation cephalosporins and Fluoroquinolones has shown an increased annual resistance rate of gram-negative bacterial strains. The results showed a positive significant correlation between two quarterly lagged numbers of BLBLIs that indicated increased susceptibility to the resistance potential of the strains, whereas levofloxacin and meropenem exhibited no association with resistance to the infections. **Conclusion:** The usage of BLBLIs showed promising results against infections, still, it required a cautious planning and wide understanding of acquiring and sustaining resistance to BLBLIs and its associated antibiotics at the clinical level.

**Keywords:** Piperacillin/Tazobactam, Ceftazidime, Klebsiella pneumoniae, B-Lactam/ B-lactamase inhibitors

## INTRODUCTION

The emergence of B-lactam-hydrolysing enzyme, B-lactamases has been known to be a remarkable threat and considered to be a clinical challenge as its virulent capability in responding to environmental inputs [1]. The enhancing rate of infections caused by Extended-Spectrum B-lactamase (ESBL) producing organisms is regarded as a global alarm due to its acquiring capacity in the hydrolytic activity of B-lactam antibiotics [2, 3]. These strains were conferring resistance to the B-lactam antibiotics such as cephalosporins and Fluoroquinolones [4-6]. As a result of worst outcomes, prolonged stays in hospital, ineffective treatment results and morbidity are prevalent in many countries caused by ESBL producing gram-negative bacteria than other strains [7, 8]. To date, more than 150 ESBL, were identified and described [4]. These B-lactamases have emerged from various genera of *Enterobacteriaceae* and *Pseudomonas aeruginosa*. To conquer this problem, alternate to Carbapenem which is being used as an effective treatment for ESBL infections in clinical practices, B-lactam/Lactamase inhibitors (BLBLIs) were instigated. Carbapenem usage and choice of antibiotics for the treatment of ESBL produced infections were based on in vitro activity and animal experiments [9, 10].

Outcomes of the treatments were subjected to conflict and highly debatable. According to Ofer *et al.*, 2015 an increased use of carbapenems contributed to the strains by

opening many resistance pathways covering point mutation to acquire the ability to hydrolyze carbapenems [11]. This led to the quest of producing effective B-Lactam antibiotics against ESBL producing pathogens. To add up the effectiveness of B-Lactam BLBLIs synergists' administration was recommended in the clinical medication [12]. Although they were believed to be effective, ESBL producing strains hydrolyze BLBLIs combination drugs also; the rate of resistance ability differs from the antibiotics such as ampicillin/Sulbactam and Piperacillin/Tazobactam against the infections [13].

Therefore, it is known that emerging challenges in conferring resistance to ESBLs related infections against

**Address for correspondence:** Dr. Wael Mansy, MBBS, MD  
Assistant Professor, Clinical Pharmacy Department, College of  
Pharmacy, King Saud University, KSA.  
Email: wsayed@ksu.edu.sa

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

**How to cite this article:** Mansy, W., Muzaheed, Rathod, S.  
Temporal association between antibiotic use and resistance in Gram-negative bacteria. Arch Pharma Pract 2020;11(2):13-8.

BLBLIs attracted the attention of many researchers and physicians worldwide. A recent study report revealed that equally efficacious alternate antibiotic agents undergo hydrolytic process against third-generation cephalosporins, specifically, Ceftriaxone and Cefotaxime were directly implied that prescribed and consumed antibiotics were unsuited for the treatment of ESBL associated infections.<sup>[2]</sup> In an earlier study, it was reported that the use of BLBLIs combination has altered its molecular point resulted mutant for developing susceptibility in antibiotic resistance to the inhibitors<sup>[14]</sup>. Wong-Beringer *et al.*, 2002 stated that ceftazidime treatment was unsuccessful in treating ESBL producing pathogens. Besides, increased use of carbapenems against ESBL-EK infections was occurred, simultaneously; the emergence of carbapenems resistance developed in associated other pathogens<sup>[15]</sup>.

However, there are close association existing between prescribed consumption of antibiotics and antimicrobial resistance to the prevalent ESBL producing pathogens, is still not understood obviously. The present study was carried out with an objective of wide understanding of the association between usage of antibiotics and resistance rate to BLBLIs, third-generation cephalosporins, all Fluoroquinolones, against prevalent pathogens of ESBLIs such as *K.Pneumoniae*, *Acinetobacter*, and *Pseudomonas aeruginosa* species

## MATERIALS AND METHODS

### Collection of Data on Prescription of Antibiotic

Before starting data collection, ethical approval was obtained from the ethics research committee with a registration number GURP/2019/43 reviewed by the institutional review board of Gulbarga University, Karnataka, India. The date on consumption and prescription of antibiotics for a tenure of 2014 – 2017, was collected from the public health department database. It is a predominant database pool that includes 98% of prescription details to the patients of Karnataka State, India. Coding for the antibiotics was followed by WHO and anatomical therapeutic chemical classification (ATC)<sup>[16]</sup>. As the mechanism of antibiotics against bacteria is considered to be the same in all classes. Hence, ATC classification has been accepted and used to analyze the relationship between the occurrence of prevalence isolates resistance efficacy and on the different antibiotic exposure<sup>[17, 18]</sup>. In the present study, data on the prescription of antibiotics specifically to BLBLIs treatment choice (ATC code JOICR) covering 3<sup>rd</sup> generation Cephalosporins and Fluoroquinolones were added for the analysis.

### Collection of Data on Antimicrobial Resistance Efficacy:

The database on microbial culture was derived from the above-designated specialty hospital and complied with to evolve a quarterly estimate for the antimicrobial resistance

(ARN). It is noteworthy that data derived hospital has been declared as an "Antimicrobial resistance monitoring focal point" by the WHO during 1988 with 2200 beds. The required microbial specimens were received from both outpatient and inpatient departments and further identification and susceptibility tests were also carried out in electronic Automated system (Vitek, bioMerieux) or else disk diffusion tests were performed followed by clinical laboratory standards institute (CLSI) guidelines (ARN). To represent BLBLIs 3<sup>rd</sup> generation Cephalosporins and Fluoroquinolones, drugs such as Piperacillin/Tazobactam and Ceftazidime were applied respectively. In the collection of the database on resistance, duplicates isolates and intermediate susceptible samples were avoided in this study. The rate of resistance was calculated by applying the following formula as the number of resistance isolates divided by the number of tests in each annum.

### Statistical analysis

To analyze and identify the trends of antibiotic prescriptions and resistant ability was carried out by applying regression analysis. If P-value showed less than 0.05 with R square values greater than 0.3 are considered to be statistically significant<sup>[19]</sup>. To assess the association between a quarterly number of antibiotic prescription and quarterly isolation rate of antibiotic susceptibility, a cross-correlation was executed<sup>[20]</sup>. The Box-Jenkins method was also performed to analyze time-series data on autoregressive moving average models<sup>[21, 22]</sup>. Outcomes were evaluated using the Dickey-Fuller test applied to find out if spurious correlations to be ruled out. Akaike information criterion test portmanteau tests were also carried out<sup>[23]</sup>. All statistical analysis was performed in R version 3.2.4.

## RESULTS

During the study period (2014-17) mean value of annual antibiotic prescription was recorded as 16,127 with a range of 3782-51469 numbers covering all BLBLIs, third-generation Cephalosporins, fluoroquinolones, Aminoglycosides, Carbapenems, and Macrolides. The average number of prescription and consumption of all BLBLIs was found to be 41,107 with (34768-51469 range). Third generation Cephalosporins, Fluoroquinolones and Aminoglycosides annual averages are recorded as 27599 with a range of (24646-37426), 16,917 with a range of (9707-25858) and 24,664 numbers with a range of (14668-31549) respectively. Similarly, average annual numbers of prescription rate on Carbapenems and Macrolides were found to be 18087 with a range of (14456-27491) and 9454 range from (9707-15858) respectively. It was noticed that no remarkable deviation was observed in the prescription rate throughout the study period (**Table 1**).

Annual Mean Value of rate of resistance of major pathogen, *K. Pneumoniae* to the antibiotic Piperacillin/Tazobactam, Ceftazidime, Levofloxacin, Ciprofloxacin, Gentamicin, and Meropenem was found to be 38.2%, 29.3, 27.17, 57.8, 53.5

and 5.02% respectively. Whereas Azithromycin value was not determined (NA). The average value of yearly resistance rate of *Acinetobacter* to the prescribed antibiotics was recorded such as Piperacillin/Tazobactam (42.02%), Ceftazidime (32.24%), Levofloxacin (29.7%), Ciprofloxacin (63%), and Gentamicin (59.6%) Meropenem (5.4%) and Azithromycin was observed and showed as 21.15%. Similarly, the value of *Pseudomonas Aeruginosa* resistance rate was recorded as 46.2%, 35.46, 32.87, 69.6, 64.94 and 6.07% to the respective antibiotics such as Piperacillin/Tazobactam, Ceftazidime, Levofloxacin, Ciprofloxacin, Gentamicin, and Meropenem, whereas Azithromycin value was also N.D. (Not Determined) (**Table 2**).

As a result of bivariate analysis on the major antibiotic resistance, *K. Pneumoniae* showed a positive significant

correlation with two quarterly lagged numbers of BLBLIS such as piperacillin/Tazobactam ( $\beta=0.56$ ;  $p<0.05$ ), ceftazidime ( $\beta=0.62$ ;  $p=0.05$ ) and ciprofloxacin ( $\beta=0.56$ ;  $p<0.05$ ) whereas levofloxacin ( $\beta=0.40$ ;  $p=0.01$ ) and meropenem ( $\beta=-0.250$ ;  $p=0.01$ ) showed no correlation. Moreover, the lagged quarterly number Cephalosporins prescription was also significantly correlated with *K.Pneumoniae* resistance to Ceftazidime ( $\beta=0.54$ ;  $P<0.05$ ) in two-quarter Levofloxacin ( $\beta=0.59$ ;  $P<0.03$ ) and Meropenem ( $\beta=0.39$ ;  $P=0.055$ ) One quarter lag number. However, all fluoroquinolones prescription to *K.pneumoniae* resistance had no association to ceftazidime ( $\beta=0.24$ ;  $p<0.01$ ) two-quarter lags, ciprofloxacin, meropenem, levofloxacin, and their values were found to be ( $\beta=0.26$ ;  $P=0.02$ ); ( $\beta=0.07$ ;  $P=0.05$ ) and ( $\beta=0.27$ ;  $P=0.35$ ) respectively (**Table 3**).

**Table 1:** Prescription rate throughout the study period

Antibiotics	The annual mean number of antibiotics prescriptions				
	2014	2015	2016	2017	
$\beta$ -lactam/ $\beta$ -lactamase inhibitors	41,344 (33,799–50,123)	43,635 (33,556–4,568)	42,937 (38,660–6,667)	38,183 (27,001–50,628)	41,107 (34,768–51,469)
Third-generation cephalosporins	37,982 (30,586–50,543)	38,870 (30,248–7,164)	30,947 (24,663–4,567)	23,404 (22,789–36,510)	27,599 (24,646–37,426)
Fluoroquinolones	17,580 (16,353–23,003)	18,973 (15,910–5,796)	16,549 (11,090–5,856)	15,540 (12,446–22,029)	16,917 (09,707–25,858)
Aminoglycosides	24806 (23,099–30,126)	26181 (13,656–4,580)	25761 (18,696–6,637)	22909 (17,901–30,642)	24664 (14,668–31,549)
Carbapenems	18191 (10,866–20,453)	19199 (10,845–7,445)	18892 (14,396–4,777)	16800 (12,859–26,160)	18087 (14,456–27,496)
Macrolides	9509 (6,353–13,903)	10036 (5,910–15,576)	9875 (8,090–15,656)	8782 (7,446–12,029)	9454 (9,707–15,858)

**Table-2a:** Antibiotic resistance rate to *Klebsiella pneumoniae* throughout the study period

Antibiotics	Isolation rate (%) of antibiotic-resistant <i>Klebsiella pneumoniae</i>			
	2014	2015	2016	2017
Piperacillin/Tazobactam	36.9	38.25	36.25	41.4
Ceftazidime	25.875	34.65	24.3	32.4
Levofloxacin	23.625	26.1	29.25	29.7
Ciprofloxacin	53.66	56.343	59.16015	62.1181575
Gentamicin	49.66	52.143	54.75015	57.4876575
Meropenem	4.66	4.893	5.13765	5.3945325
Azithromycin	ND	ND	ND	ND

**Table-2b:** Antibiotic resistance rate to *Acinetobacter baumannii* throughout the study period

Antibiotics	Isolation rate (%) of antibiotic-resistant <i>Acinetobacter baumannii</i>			
	2014	2015	2016	2017
Piperacillin/Tazobactam	40.59	42.075	39.875	45.54

Ceftazidime	28.4625	38.115	26.73	35.64
Levofloxacin	25.9875	28.71	32.175	32.67
Ciprofloxacin	59.026	61.9773	65.076165	68.32997325
Gentamicin	54.626	57.3573	60.225165	63.23642325
Meropenem	5.126	5.3823	5.651415	5.93398575
Azithromycin	21.66	22.96	22.11	19.15

**Table-2c:** Antibiotic resistance rate to *Pseudomonas aeruginosa* throughout the study period

Antibiotics	Isolation rate (%) of antibiotic-resistant <i>Pseudomonas aeruginosa</i>			
Piperacillin/Tazobactam	44.649	46.2825	43.8625	50.094
Ceftazidime	31.30875	41.9265	29.403	39.204
Levofloxacin	28.58625	31.581	35.3925	35.937
Ciprofloxacin	64.9286	68.17503	71.5837815	75.16297058
Gentamicin	60.0886	63.09303	66.2476815	69.56006558
Meropenem	5.6386	5.92053	6.2165565	6.527384325
Azithromycin	ND	ND	ND	ND

**Table-3:** Antibiotic-resistant *Klebsiella pneumoniae*

	Antibiotics				
	Piperacillin/Tazobactam	Ceftazidime	Levofloxacin	Ciprofloxacin	Meropenem
$\beta$ -lactam/ $\beta$ -lactamase inhibitors	0.56 p < 0.05 2 quarters lag	0.62 p = 0.05 2 quarters lag	-0.40 p = 0.01 2 quarters lag	0.56 p < 0.05 2 quarters lag	-0.250 p = 0.01 2 quarters lag
Third-generation cephalosporins	-0.11 p = 0.35	0.54 p < 0.05	0.59 p = 0.03	-0.19 p = 0.61	0.39 p = 0.055
Fluoroquinolones	- p = 0.19	2 quarters lag 0.24 p < 0.01	1 quarter lag 0.27 p = 0.35	- p = 0.22	1 quarter lag 0.07 p = 0.05
	-	2 quarters lag	-	-	-

**Table 4:** Percentage of the rate of Isolation of antibiotic-resistant against ESBL producing pathogens

Antibiotic	<i>Klebsiella</i>	<i>Acinetobacter</i>	<i>Pseudomonas</i>
Piperacillin/Tazobactam	88.2	42.02%	46.23
Ceftazidime	29.3	32.24%	35.46
Levofloxacin	27.17	29.7	32.87
Ciprofloxacin	57.8	63.5	69.95
Gentamicin	53.5	59.6	64.74
Meropenem	5.02%	5.4	6.078
Azithromycin	ND	21.15	ND

## DISCUSSION

The increasing rate of production of ESBL producing strains such as *K. pneumoniae*, *Acinetobacter* and *Pseudomonas* species were limiting the clinical therapeutic practices [7, 10,

24]. BLBLIs such as Piperacillin/Tazobactam, Third generation Cephalosporins are recognized as an alternate antibiotic choice against infections [25]. Even though Carbapenems is believed to be effective, it is evident that consumption has led to the unsuccessful results in the

treatments of ESBL producing pathogens and outcomes of treatment has been debatable. However, all the evidence showed that BLBLIs have equal efficacy comparing with Carbapenems and known to be an alternate antibiotic agent to Carbapenem drugs [26].

To develop an appropriate protocol for BLBLIs, as other options for Carbapenem, it is mandatory to test the association between BLBLIs and resistance capability of antimicrobial pathogens. Similar earlier studies have focused on the association/correlation between seasonality and antibiotic usages [17, 18, 27]. In the present investigation, a significant association was observed between all prescribed and consumed BLBLIs showed the greatest at a time occurrence of association to the Piperacillin/Tazobactam, Ceftazidime, Levofloxacin, Ciprofloxacin and Meropenem resistance in *K.Pneumoniae*. Whereas Third generation Cephalosporins and Fluoroquinolones showed insignificant correlation. This may be attributed to the selection of pressure of antibiotic usage on the predominant of resistance isolates strains [28]. Our study results were agreed with the findings of Lai *et al.*, 2011 found that a significant correlation between Piperacillin/Tazobactam usage and its resistance ability [29]. Our investigation has also revealed that one of the antibiotics administered ceftazidime resistance in *K.Pneumoniae* showed a positive correlation with entire BBLIs, Third generation Cephalosporins and Fluoroquinolones statistically. In *Klebsiella*, the maximum annual mean resistance rate was observed to the ciprofloxacin (57.87%) followed by gentamicin (53, 5%) whereas the minimum rate was recorded as (29.3%) to the ceftazidime. In *Acinetobacter*, the Annual maximum resistance rate was found to be (63%) to the ciprofloxacin followed by gentamicin (63%) with minimum value to the meropenem (5.4%). Similarly, *Pseudomonas* species showed a maximum value of annual resistance rate exhibited to the ciprofloxacin ((69.9%) followed by gentamicin (64.74%) and minimum to meropenem and recorded as (6.007%).

An earlier report on *Klebsiella* species showed a significant positive correlation with BBLIs Cephalosporins and fluoroquinolones in clinical investigation [30]. This may be presumed that Fluoroquinolone resistance might have attributed to the transferable plasmid within ESBL producing strains [31]. Overall that correlation may be due to the potential of providing resistance to all classes of antibiotics [28]. No correlation was observed in Levofloxacin resistance in *K. Pneumoniae* in the present study. It also indicated all BLBLIs consumption was positively correlated while Levofloxacin showed negatively associated. This finding may due to the instability of a quarterly number of Fluoroquinolones advised and consumed.

## CONCLUSIONS

In the present investigation, a remarkable association was identified between BLBLIs medication and

piperacillin/Tazobactam resistance was found to be an increasing trend to the *K.pneumoniae*, *Acinetobacter* and particularly to *Pseudomonas* pathogenic strains. Our results suggested that to maintain the potential of resistance of the strains not to develop, usage of BLBLIs has been recommended to minimize clinical practices. The intervention of An alternate possible choice has been appreciated and it is considered to be the eleventh hour. Moreover, as a result of our study, it is to opine that prolonged prescription and usage of BLBLIs against tested pathogenic strains has indicated the emerging of resistance ability. Although several studies were emphasized to these inhibitors, inconsistent results were observed in our investigation. We further argued that a focus intervention is necessary to avoid perpetuation of resistance power to the BLBLIs.

## REFERENCES

1. Drawz, Sarah M., Krisztina M. Papp-Wallace, Robert A. Bonomo. New  $\beta$ -lactamase inhibitors: a therapeutic renaissance in an MDR world. *Antimicrobial agents and chemotherapy*, 2014; 58(4): 1835-1846.
2. Tamma, Pranita D., Jesus Rodriguez-Baño. The use of noncarbapenem  $\beta$ -lactams for the treatment of extended-spectrum  $\beta$ -lactamase infections. *Clinical Infectious Diseases*, 2017; 64(7): 972-980.
3. Bol TS, Iida M, Mostafa S. Antibiotic Resistance Trend of Uropathogens in a Tertiary Teaching Hospital in Rasht Iran a Longitudinal Study. *Int. J. Pharm. Phytopharm. Res.* 2019;9(2):98-102.
4. Bradford, Patricia A. Extended-spectrum  $\beta$ -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clinical microbiology reviews*, 2001; 14(4): 933-951.
5. Paterson, David L., Wen-Chien Ko, Anne Von Gottberg, Sunita Mohapatra, Jose Maria Casellas, Herman Goossens, Lutfiye Mulazimoglu *et al.* Antibiotic therapy for *Klebsiella pneumoniae* bacteremia: implications of production of extended-spectrum  $\beta$ -lactamases. *Clinical Infectious Diseases*, 2004; 39(1): 31-37.
6. AlOsaimi K.M, Kambal A.M, AlOtaibi F.M, AL-Anazi A.B, AlMotairi A.R, AlGhamdi W.M, Altujjar A.R. Factors Affecting Physicians' Choice of Antibiotics for Treatment of Community Acquired Urinary Tract Infections and Their Correlation with Antimicrobial Susceptibility Test Results in King Khalid University Hospital during 2013-2014. *Int. J. Pharm. Res. Allied. Sci.* 2018;7(1):19-25.
7. Stone, Patricia W., Archana Gupta, Maureen Loughrey, Phyllis Della-Latta, Jeannie Cimiotti, Elaine Larson, David Rubenstein, and Lisa Saiman. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* outbreak in a neonatal intensive care unit. *Infection Control & Hospital Epidemiology*, 2003; 24(8): 601-606.
8. Almazroea AH, Almuzheerbi SI, Alamri MA, Alloqmani MM, Almohammadi GA, Bazarbay AA, Khoshhal BA. Prevalence of Antibiotic Use for Pediatric Acute Viral Gastroenteritis in Medinah Medicine Almunwarah, KSA. *Pharmacophores.* 2019 Nov 1;10(6):37-49.
9. Vardakas, Konstantinos Z., Giannoula S, Tansarli, Petros I, Rafailidis, and Matthew E. Falagas. "Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  $\beta$ -lactamases: a systematic review and meta-analysis." *Journal of antimicrobial chemotherapy*, 2012; 67(12): 2793-2803.
10. Paterson, David L., and Robert A. Bonomo. Extended-spectrum  $\beta$ -lactamases: a clinical update. *Clinical microbiology reviews*, 2005; 18(4): 657-686.



11. Ofer-Friedman, Hadas, Coral Shefler, Sarit Sharma, Amit Tirosh, Ruthy Tal-Jasper, Deepthi Kandipalli, Shruti Sharma et al. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. *infection control & hospital epidemiology*, 2015; 36(8): 981-985.
12. Drawz, Sarah M., Robert A. Bonomo. Three decades of  $\beta$ -lactamase inhibitors. *Clinical microbiology reviews*, 2010; 23(1): 160-201.
13. Piroth, Lionel, Hervé Aubé, Jean-Marc Doise, Michel Vincent Martin. "Spread of Extended-Spectrum  $\beta$ -Lactamase—Producing *Klebsiella pneumoniae*: Are  $\beta$ -Lactamase Inhibitors of Therapeutic Value?." *Clinical infectious diseases*, 1998; 27(1): 76-80.
14. Belaouaj, Azzaq, Claudine Lapoumeroulie, Maria Manuela Caniça, Gérard Vedel, Pierre Névoz, Ragopal Krishnamoorthy, and Gérard Paul. Nucleotide sequences of the genes coding for the TEM-like  $\beta$ -lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). *FEMS microbiology letters*, 1994; 120(1-2): 75-80.
15. Wong-Berlinger, Annie, Janet Hindler, Michael Loeloff, Anne Marie Queenan, Nancy Lee, David A. Pegues, John P. Quinn, and Karen Bush. Molecular correlation for the treatment outcomes in bloodstream infections caused by *Escherichia coli* and *Klebsiella pneumoniae* with reduced susceptibility to ceftazidime. *Clinical Infectious Diseases*, 2002; 34(2): 135-146.
16. World Health Organization. 2016. WHO Collaborating Centre for Drug Statistics Methodology. Structure and principles. [http://www.whocc.no/atc/structure\\_and\\_principles](http://www.whocc.no/atc/structure_and_principles). Accessed 2 Aug 2017.
17. Goossens, Herman, Matus Ferech, Robert Vander Stichele, Monique Elseviers, and ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *The Lancet*, 2005; 365(9459): 579-587.
18. Goossens H. Antibiotic consumption and link to resistance. *Clin Microbiol Infect*. 2009; 15:12-5.
19. Hsu, Li-Yang, Thean-Yen Tan, Vincent H. Tam, Andrea Kwa, Dale Andrew Fisher, Tse-Hsien Koh. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. *Antimicrobial agents and chemotherapy*, 2010; 54(3): 1173-1178.
20. Gilca, Rodica, Élise Fortin, Charles Frenette, Yves Longtin, Marie Gourdeau. Seasonal variations in *Clostridium difficile* infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada. *Antimicrobial agents and chemotherapy* 2012; 56(2): 639-646.
21. Cowpertwait PSP, Metcalfe AV. *Introductory time series with R*. New York: Springer; 2009.
22. Box GEP, Jenkins GM, Reinsel GC. *Time series analysis: forecasting and control*, 3rd ed. Englewood cliffs, NJ: prentice hall, 1994. Helfenstein U. Box-Jenkins modelling in medical research. *Stat Methods Med Res*. 1996; 5:3–22.
23. Hyndman RJ, Athanasopoulos G. *Forecasting; principles and practice*. New York: O Texts; 2014.
24. Harris, Patrick NA, Mo Yin, Roland Jureen, Jonathan Chew, Jaminah Ali, Stuart Paynter, David L. Paterson, Paul A. Tambyah. Comparable outcomes for  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant *Escherichia coli* or *Klebsiella pneumoniae*. *Antimicrobial resistance and infection control*, 2015; 4(1): 14.
25. Ng, Tat Ming, Wendy X. Khong, Patrick NA Harris, Partha P. De, Angela Chow, Paul A. Tambyah, David C. Lye. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. *PLoS One*, 2016; 11(4).
26. Tamma, Pranita D., Jesus Rodriguez-Baño. The use of noncarbapenem  $\beta$ -lactams for the treatment of extended-spectrum  $\beta$ -lactamase infections. *Clinical Infectious Diseases*, 2017; 64(7): 972-980.
27. Sun, Lova, Eili Y. Klein, Ramanan Laxminarayan. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. *Clinical infectious diseases*, 2012; 55(5): 687-694.
28. Liu X, Thungrat K, Boothe DM. Occurrence of OXA-48 carbapenemase and other  $\beta$ -lactamase genes in ESBL-producing multidrug resistant *Escherichia coli* from dogs and cats in the United States, 2009-2013. *Front Microbiol*. 2016; 7:e1057.
29. Lai, Chih-Cheng, Cheng-Yi Wang, Chen-Chen Chu, Che-Kim Tan, Ching-Lan Lu, Yi-Chieh Lee, Yu-Tsung Huang, Ping-Ing Lee, Po-Ren Hsueh. Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. *Journal of antimicrobial chemotherapy*, 2011; 66(6): 1374-1382.
30. Jacoby, T. S., R. S. Kuchenbecker, R. P. Dos Santos, L. Magedanz, P. Guzzato, L. B. Moreira. Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit. *Journal of Hospital Infection* 2010; 75(1): 23-27.
31. Wang, Minggu, Daniel F. Sahn, George A. Jacoby, David C. Hooper. Emerging plasmid-mediated quinolone resistance associated with the *qnr* gene in *Klebsiella pneumoniae* clinical isolates in the United States. *Antimicrobial agents and chemotherapy* 2004; 48(4): 1295-1299.